May has been an eventful month where we took yet another important step forward. The number of active billable Dosell units increased by an additional 14% from April – a growth now built on an ever-larger base volume. At the same time, we passed a major symbolic milestone: more than 1,000 active units in operation, showing that we’ve made it through the most challenging phase – building a stable, scalable, and in-demand solution.
Growth is driven both by more municipalities and partners starting to use Dosell – and by existing customers prescribing more units per client. We are seeing broad and growing traction, even though we’re still coming from relatively modest volumes. That makes the strength of our growth rate all the more encouraging.
We are now entering the summer months, which traditionally means a somewhat slower pace due to holidays. But we look forward to ramping up again in the fall – firmly anchored in our long-term strategy.
Sweden: Growth in VGR and Increasing Demand Ahead of Autumn In May, two more municipalities in the Västra Götaland region (VGR) began using Dosell, bringing our presence in the region to 14 municipalities. Several of these have started increasing their internal volumes and are receiving very positive feedback from both staff and users.
Two new municipalities have approved pilot projects with Dosell set to start right after summer. We’ve also held numerous presentations for municipalities now considering launching their own pilots – a clear sign of the strong momentum we’re experiencing in the Swedish public care sector.
At Vitalis, the Nordic region’s leading event for health and social care, we gained strategic traction – both through our presence and by presenting collaborations with Tamro, JDM Innovation, and Phoenix Group. The reaction from visitors was overwhelmingly positive, summarized best by the comment: “Finally, two solutions in one system!”
Especially appreciated was our joint stage appearance with ATEA and Ulricehamn Municipality, where Ulricehamn shared their successful implementation and how their “slow and steady” approach has led to stable, positive development. Many home care teams in the municipality are now reaching out, eager to start using Dosell themselves.
We also participated in Senior Day in Kungsträdgården, where we received great interest in our consumer solution. At the same time, our partner Zafe exhibited at the Dementia Days event, where Dosell attracted significant attention for its value in early intervention for cognitive impairment. The new Social Services Act emphasizes this very need – and many now see Dosell as a key part of the solution.
Spain: Pharmacy Network and Interest from Private Care Providers In Spain, our partner Ti Medi continues rolling out Dosell through the national pharmacy network, which includes over 1,500 pharmacies.
Following strong media attention in April, private care providers have also started to show interest in Dosell. Our B2B solution is now being actively presented to these providers, who see the opportunity to complement their existing care structures with a digital solution that enhances independence and safety in medication management.
The Netherlands: Continued Growth and Trade Fair Momentum In the Netherlands, growth continues at a rapid pace. Our customer TCCN is highly engaged and has established an efficient approach for broad outreach – already leading to concrete meetings with new stakeholders. At the same time, their existing customers are increasing their volumes month over month.
Dosell TV has generated strong interest, and our presence at the April trade fair served as a clear catalyst for new contacts. Several of these are now in the quotation or implementation phase. The combination of proactive sales, a strong network, and a value-driven offering that meets real needs gives us excellent conditions for continued expansion together with TCCN.
Strategic Partnership – LOI with JDM Innovation In May, we signed a Letter of Intent with JDM Innovation, aiming to establish a strategic partnership in Europe. JDM is a well-established player in logistics, automation, and medical technology, working with both international pharmaceutical companies and pharmacy chains.
The partnership creates opportunities to integrate our technologies and opens doors to new markets in Europe. Discussions around joint pilots are already underway, and we see great potential in driving efficiency and safe medication management together in new markets.
Celebrate the 1,000-Unit Milestone with Us – Investor Evening June 12 To mark our achievement of surpassing 1,000 active units, we’re inviting you to an investor evening in Stockholm – on Thursday, June 12.
We sincerely hope as many shareholders as possible will take this opportunity to come, meet our team in person, ask questions, and get deeper insight into our journey and future vision. It’s a great chance to connect – and to experience Dosell live.
Thank You for Your Trust – Together We Are Shaping the Future of Medication Management iZafe Group is in a phase of strong commercial momentum. May’s results confirm both the direction and pace of our progress. We’re strengthening our partnerships, expanding our network, and building on a model that has now proven both scalable and effective.
Thank you for following our journey – and we warmly welcome you to the investor evening on Thursday, June 12.
iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that its subsidiary Dosell has reached a significant milestone: more than 1,000 active Dosell units are now in use across Europe. This marks a clear breakthrough for safe and digital medication management in the home.
To celebrate this achievement, the company invites shareholders, partners, healthcare professionals and other stakeholders to an exclusive event at its Stockholm office on June 12.
“This milestone is both personal and strategic. Reaching 1,000 Dosell units in operation proves that we’ve made it through the most challenging phase – building a stable, scalable and in-demand solution. Now we’re ready to grow in earnest. None of this would have been possible without the tremendous dedication of our team, our partners, and our shareholders who believed in us every step of the way. I look forward to sharing the next chapter with you,” says Anders Segerström, CEO of iZafe Group.
During the evening, we will share the journey toward reaching 1,000 active Dosell units – the challenges we’ve faced, the key turning points, and why this moment represents a breakthrough for both our company and the digital healthcare sector.
You’ll also get a glimpse of what’s coming next – our strategic goals, technical roadmap, and how we plan to scale up the business both in Sweden and internationally.
Food and drinks will be served in a relaxed setting where you’ll have the opportunity to connect with the Dosell team, fellow shareholders, healthcare innovators, and industry professionals.
Event Details:
Date: Wednesday, June 12
Time: From 6:00 PM
Location: iZafe Group HQ, David Bagares Gata 3A, Stockholm
Please note that registration is required and space is limited – spots will be allocated on a first-come, first-served basis.
About Dosell Dosell is a medical technology solution that ensures the right person takes the right medication at the right time. The product is specifically designed to prevent double dosing and improve adherence – one of the greatest challenges in modern healthcare. Dosell is currently used by municipalities, private care providers and partners across Europe.
Årsstämman i iZafe Group AB, orgnr. 556762-3391, (”Bolaget”) ägde rum torsdagen den 28 maj 2025 på Bolagets kontor. Årsstämman beslutade, bland annat följande:
Fastställande av resultat- och balansräkning Fastställande av resultat- och balansräkning för moderbolaget och koncernen för räkenskapsåret 2024.
Utdelning Stämman beslutade att ingen utdelning lämnas och att årets resultat balanseras i ny räkning.
Styrelse och revisor Stämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2024.
Stämman beslutade att styrelsen ska bestå av fyra ordinarie ledamöter utan suppleanter. Stämman beslutade om omval av Richard Wolff till styrelseordförande samt om omval av Jenny Styren till ordinarie styrelseledamot. Stämman beslutade om nyval av Anna Håkansson och Samuel Danofsky till styrelseledamöter. Den auktoriserade revisorn Johan Kaijser omvaldes till Bolagets revisor för tiden intill slutet av nästa årsstämma.
Styrelse- och revisorsarvode Stämman fastställde styrelsearvode med 117 600 kronor och arvode till styrelseordförande med 176 400 kronor. Alla ersättningar som en styrelseledamot erhåller från Bolaget i enhetlig med godkända uppdragsavtal kan avräknas mot styrelsearvodet. Arvode till revisorn ska utgå enligt godkänd räkning.
Bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler Stämman fastställde att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet. Nyemission av aktier eller emission av teckningsoptioner eller konvertibler ska ske till marknadsmässiga villkor och ska kunna ske med eller utan företrädesrätt för aktieägarna samt med eller utan bestämmelse om apport, kvittning eller andra villkor.
Ändring av bolagsordningen samt minskning av aktiekapitalet för avsättning till fritt eget kapital Stämman beslutade om ändring av bolagsordningens gränser för aktiekapitalet från lägst 50 000 000 kronor och högst 200 000 000 kronor till lägst 15 000 000 kronor och högst 60 000 000 kronor, samt om minskning av aktiekapitalet med 46 527 925,65 kronor för avsättning till fritt eget kapital. Minskningen av aktiekapitalet sker utan indragning av aktier. Efter minskningen av aktiekapitalet kommer Bolagets aktiekapital att uppgå till 15 509 308,55 kronor, fördelat på sammanlagt 310 186 171 aktier, varav 600 000 A-aktier som ger rätt till tio (10) röster per aktie på bolagsstämma och 309 586 171 B-aktier som ger rätt till en (1) röst per aktie på bolagsstämma. Samtliga aktier kommer efter minskningen att ha ett kvotvärde om 0,05 kronor per aktie. Beslutet om minskning av aktiekapitalet kräver tillstånd från Bolagsverket eller allmän domstol.
iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that it has signed a Letter of Intent (LOI) with German company JDM Innovation GmbH, part of the PHOENIX group. The goal is to initiate a strategic partnership where the Dosell medication robot will be integrated with JDM’s dispensing solution Smila into a joint digital platform for home-based medication management. The solution is aimed at municipalities and care providers across Europe and is designed to simplify implementation, increase adherence, and free up valuable time in healthcare delivery.
JDM has more than 40 years of experience in digital healthcare solutions and is the developer of Smila – an automatic medication dispenser already in use in Finland and Denmark. In Sweden, Smila is being introduced in collaboration with Tamro AB. The PHOENIX group, to which both JDM and Tamro belong, is the European leader in pharmaceutical wholesale, pharmacy retail, and services for the pharmaceutical industry with operations in 29 healthcare markets, providing a strong foundation for European expansion.
Dosell, developed by iZafe, is a Swedish medication robot used in elder care to ensure safe and accurate medication intake at home. The solution is currently established in a growing number of municipalities in Sweden and care organizations in the Netherlands and Spain, with increasing interest from other European markets. The technology has proven to reduce medication errors, enhance patient safety, and save valuable time for healthcare staff – making it possible to deliver high-quality care to more individuals.
Through this partnership, two complementary solutions are brought together in one integrated platform. Municipalities and care providers gain access to a unified system where a single training and technical integration unlock two proven technologies – streamlining procurement, implementation, and day-to-day use.
“This is an important strategic step for iZafe. By combining our solution with Smila and leveraging PHOENIX group’s strong presence in Europe, we are creating new opportunities for growth. Together, we are making it easier for municipalities and care providers to deliver safe and effective medication management to more users,” says Anders Segerström, CEO of iZafe Group.
Both iZafe and JDM advocate that different users have different needs. With this new platform, municipalities can easily offer tailored solutions based on each user’s abilities – without compromising on safety or ease of use. The platform ensures smooth implementation and effective daily operations, helping staff save time and enabling more people to receive high-quality care.
“Dosell is a perfect complement to Smila. Together, we can offer a strong end-to-end solution on one platform that simplifies the implementation of digital medication management for municipalities across Europe,” says Martin Lafleur, CEO of JDM Innovation GmbH.
This week, Dosell will exhibit together with Tamro at Vitalis – the Nordic region’s leading event for the future of health, care, and welfare technology. The collaboration will be presented under the joint message: “Two brands. One vision. One platform.”
April was a month marked by concrete expansion, deepened customer relationships, and sustained strong interest from new stakeholders. After a 12% increase in billable Dosell units in March, we grew by an additional 19% in April. This is a clear sign that our strategy is effective and that the need for digital medication management continues to rise. As it stands, we expect to reach an important milestone in May – 1,000 active billable units. This is a symbolically strong threshold that reflects both our momentum and that we are now truly beginning to scale.
Dosell continues to earn trust – both as a practical everyday tool and as a key enabler in the transition to future-oriented healthcare. Our momentum remains strong, and the interest from new municipalities and partners shows that the market is moving.
Sweden: Broad Implementation in VGR and Strong Demand In April, two additional municipalities in the Västra Götaland Region (VGR) launched Dosell. In total, 12 municipalities in the region are now operational, and we’re seeing most of them move from pilot projects into broad implementation. This, in turn, has encouraged other municipalities – previously hesitant – to reach out and express interest in introducing Dosell.
We also conducted 10 demonstrations for municipalities currently evaluating pilot projects. One municipality launched a pilot in April, and the results so far have been very positive – no alerts have been triggered, and users report high satisfaction.
In addition, we are now engaged in exciting conversations with new potential partners who are highly interested in Dosell and its user-friendly design. We are in a phase where more stakeholders are recognizing both the need for and the potential of a solution that simplifies care, reduces strain, and empowers users.
We also participated in Seniors’ Day on May 6 in Stockholm’s Kungsträdgården – a gathering for over 60,000 seniors. We presented both Dosell and our consumer version and were met with strong interest from the target audience. The overall development in Sweden demonstrates that our solution has gained a firm foothold and continues to grow organically through strong results and word-of-mouth.
The Netherlands: 21% Growth and New Clients from the Expo In the Netherlands, our partner TCCN continues to deliver strong results. The number of active Dosell units increased by 21% from March to April, and the customer base is expanding.
Following the April expo, around 25 new leads were generated, leading to four meetings and one official offer. The first broadcast of Dosell TV also sparked significant interest, providing more organizations with insight into how Dosell works in practice.
The combination of satisfied end-users, innovative outreach, and a growing partner network provides a solid foundation for continued growth through the spring.
Spain: Market Launch and National TV Exposure In Spain, Dosell has now entered the market through our partner Ti Medi and the Savioo Home concept. After participating in expos in Barcelona and France, we are now seeing increasing media coverage.
On April 26, Dosell appeared on Spanish national television in the program Aruser on La Sexta – one of the country’s largest TV channels. Host Alfonso Arús and his panel expressed strong support for the Savioo concept and emphasized the solution’s value for elderly individuals and those with complex medication routines. This provides clear proof that Dosell is gaining attention and credibility among the general public.
Over 50 pharmacies have shown interest in offering Savioo Home, which is now being launched nationally. We hope to see a tangible increase in sales in the coming months.
Dosell’s visibility in Spain strengthens our brand in a strategically important market and sets the stage for future volume growth.
To Our Shareholders – A Solid Foundation for Growth iZafe Group remains in a development phase – but April clearly demonstrates that our strategy is bearing fruit. We are strengthening our position in Sweden through expanded cooperation in VGR, deepening our presence in Europe through new client relationships in the Netherlands, and reaching the general public in Spain through national TV.
At the same time, we are continuously engaging in new partnership discussions, and we see more readiness than ever to take action. The demand for safe, efficient medication management is growing rapidly – and Dosell is well positioned to meet that challenge.
Thank you for your continued trust and for following our journey forward.
Aktieägarna i iZafe Group AB, org.nr 556762–3391 (”iZafe” eller ”Bolaget”), kallas härmed till årsstämma den 28 maj 2025 kl. 14:00 på Bolagets lokaler på David Bagares Gata 3, Stockholm. Inregistrering inleds från klockan kl. 13:45.
RÄTT ATT DELTA OCH ANMÄLAN
Aktieägare som önskar delta på bolagsstämman ska
dels vara införd i den av Euroclear Sweden AB förda aktieboken den 20 maj 2025,
dels senast den 22 maj 2025 anmäla sig för deltagande på stämman hos Bolaget via e-post till eller per post till David bagares gata 3 BV, 111 38 Stockholm, ”Årsstämma”. Vid anmälan ska aktieägaren uppge namn, person- eller organisationsnummer, adress, och telefonnummer samt, i förekommande fall, uppgift om biträde (högst 2).
FÖRVALTARREGISTRERADE AKTIER
Aktieägare som har låtit förvaltarregistrera sina aktier måste låta registrera sina aktier i eget namn per avstämningsdagen den 20 maj 2025 för att ha rätt att delta vid årsstämman. Sådan registrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner. Rösträttsregistreringar som genomförts (dvs. är registrerade hos Euroclear Sweden AB) senast den 22 maj 2025 beaktas vid framställningen av aktieboken.
OMBUD
Aktieägare som företräds genom ombud ska utfärda skriftlig, av aktieägaren undertecknad och daterad fullmakt för ombudet. Fullmaktens giltighetstid får vara högst fem år om det särskilt anges. Anges ingen giltighetstid gäller fullmakten högst ett år. Om fullmakten utfärdas av juridisk person ska kopia av registreringsbevis eller motsvarande för den juridiska personen bifogas.
Fullmakten i original samt eventuellt registreringsbevis bör i god tid före stämman insändas per brev till Bolaget på ovan angiven adress. Fullmaktsformuläret finns tillgängligt på Bolagets webbplats (www.izafegroup.com) senast tre veckor innan stämman.
FÖRSLAG TILL DAGORDNING
Stämmans öppnande
Val av ordförande vid stämman
Upprättande och godkännande av röstlängd
Godkännande av dagordningen
Val av en eller två justeringsmän
Prövning av om stämman blivit behörigen sammankallad
Föredragning av framlagd årsredovisning och revisionsberättelse samt koncernredovisning och koncernrevisionsberättelse
Beslut om
a. om fastställande av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning;
b. om dispositioner beträffande Bolagets vinst eller förlust enligt den fastställda balansräkningen;
c. om ansvarsfrihet åt styrelsens ledamöter och verkställande direktör
Fastställande av antalet styrelseledamöter och revisorer samt suppleanter
Fastställande av styrelse- och revisorsarvoden
Val av styrelse och eventuella styrelsesuppleanter och revisorer och eventuella revisorssuppleanter
Beslut om bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler
Beslut om
ändring av bolagsordningen; samt
minskning av aktiekapitalet för avsättning till fritt eget kapital.
Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Stämmans avslutande
FÖRSLAG TILL BESLUT
Punkt 2 – Val av ordförande vid stämman
Valberedningen föreslår att stämman väljer Richard Wolff till ordförande vid bolagsstämman eller, vid förhinder, sådan annan person som styrelsen anvisar.
Punkt 8b – Beslut om disposition beträffande Bolagets vinst eller förlust enligt den fastställda balansräkningen
Styrelsen föreslår att samtliga till årsstämmans förfogande stående medel överförs i ny räkning.
Punkt 9–11 – Val av styrelse och eventuella styrelsesuppleanter samt i förkommande fall revisorer och eventuella revisorssuppleanter, fastställande av styrelse- och revisorsarvoden, val av styrelse och eventuella styrelsesuppleanter samt revisor och eventuella revisorssuppleanter
Valberedningen föreslår följande:
att styrelsen ska bestå av fyra ledamöter utan suppleanter. Antalet revisorer ska uppgå till en auktoriserad revisor utan suppleanter.
att ersättning till vardera styrelseledamoten ska utgå med 117 600 kronor (motsvarande 2 prisbasbelopp) och ersättning till styrelseordförande med 176 400 kronor (motsvarande 3 prisbasbelopp). Alla ersättningar som en styrelseledamot erhåller från Bolaget i enlighet med godkända uppdragsavtal kan avräknas mot styrelsearvodet.
att arvode till revisorn ska utgå enligt godkänd räkning.
omval av Jenny Styren och Richard Wolff som ordinarie styrelseledamöter. Göran Hermanson och Magnus Engman har avböjt omval.
nyval av Anna Håkansson och Samuel Danofsky till ordinarie styrelseledamöter.
omval av Richard Wolff som styrelseordförande.
omval av den auktoriserade revisorn Johan Kaijser på LR Revision och Redovisning Sverige AB för tiden intill slutet av årsstämman 2026.
Anna Håkansson
Anna har en mångårig och bred erfarenhet från offentlig sektor, bland annat som stadsdirektör, CFO och interimchef i flera stora organisationer. Hon har även haft uppdrag i flera pensionsstiftelser och styrelser, där hon kombinerat operativt och strategiskt ansvar. Anna är en nyfiken och resultatdriven ledare som brinner för utveckling och effektiv styrning.
Yrkeserfarenhet: Tf ekonomichef i Solna stad sedan 2023. Tidigare biträdande stadsdirektör i Stockholms stad samt stadsdirektör och CFO i Sundbybergs stad. Lång erfarenhet som finanschef i både privat och offentlig sektor.
Utbildning: Utbildad i redovisning vid Southern Illinois University, Carbondale. Styrelseutbildning från Styrelseakademien.
Annas omfattande bakgrund inom ekonomi, offentlig förvaltning och ledarskap gör henne till ett starkt tillskott i vår styrelse.
Samuel Danofsky
Samuel har lång erfarenhet inom kommunikation, politisk påverkan och opinionsbildning, särskilt inom hälso- och sjukvårdssektorn. Han har arbetat både operativt och strategiskt, såväl som rådgivare till regeringen och i ledande roller inom näringslivet. Med sin förmåga att bygga förtroende och driva komplexa kommunikationsfrågor är Samuel en värdefull förstärkning till styrelsen.
Yrkeserfarenhet: Kommunikationschef på Unilabs. Tidigare kommunikationschef på Kry samt senior rådgivare på JKL och Hallvarsson & Halvarsson. Har även varit politisk rådgivare i riksdagen och på Regeringskansliet.
Utbildning: Kandidatexamen i nationalekonomi och statsvetenskap från Uppsala universitet. Studier vid University of Michigan.
Samuels djupa förståelse för kommunikation, politik och vårdsektorns komplexitet gör honom väl rustad att bidra till vår strategiska utveckling.
Punkt 12 – Beslut om bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler
Styrelsen föreslår att årsstämman beslutar att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet.
Nyemission av aktier, liksom emission av teckningsoptioner och konvertibler, ska kunna ske med eller utan avvikelse från aktieägarnas företrädesrätt samt med eller utan bestämmelse om apport, kvittning eller andra villkor. Enligt 16 kap. aktiebolagslagen äger styrelsen inte med stöd av detta bemyndigande besluta om emissioner till styrelseledamöter i koncernen, anställda med flera.
Emission beslutad med stöd av bemyndigandet ska ske till marknadsmässiga villkor (varmed bland annat avses att marknadsmässig emissionsrabatt får lämnas) och betalning ska, förutom kontant betalning, kunna ske med apportegendom eller genom kvittning, eller eljest med villkor. Emission beslutad med stöd av bemyndigandet ska ske i syfte att tillföra Bolaget rörelsekapital, öka Bolagets finansiella flexibilitet och/eller att möjliggöra förvärv genom betalning med aktier. Om styrelsen beslutar om emission med avvikelse från aktieägarnas företrädesrätt ska skälet vara att tillföra Bolaget rörelsekapital på ett kostnads- och tidseffektivt sätt och/eller nya ägare av strategisk betydelse för Bolaget och/eller förvärv av andra företag eller verksamheter.
Punkt 13 – Beslut om (a) ändring av bolagsordningen samt (b) minskning av aktiekapitalet för avsättning till fritt eget kapital
Styrelsen föreslår att stämman beslutar om (a) ändring av gränserna för aktiekapitalet i bolagsordningen samt (b) minskning av Bolagets aktiekapital enligt nedan. Förslagen ska anses som ett förslag och därför antas av bolagsstämman som ett och samma beslut.
(a) Ändring av gränserna för aktiekapitalet i bolagsordningen Styrelsen föreslår att bolagsstämman beslutar om ändring av gränserna för aktiekapitalet i bolagsordningens § 4 från ”lägst 50 000 000 kronor och högst 200 000 000 kronor” till ”lägst 15 000 000 kronor och högst 60 000 000 kronor”.
(b) Minskning av aktiekapitalet för avsättning till fritt eget kapital Styrelsen föreslår att bolagsstämman beslutar om minskning av Bolagets aktiekapital, som för närvarande uppgår till 62 037 234,20 kronor, i enlighet med villkoren nedan:
Ändamålet med minskningen är avsättning till fritt eget kapital.
Bolagets aktiekapital ska minskas med 46 527 925,65 kronor.
Minskningen ska genomföras utan indragning av aktier.
Beslutet förutsätter ändring av bolagsordningen enligt punkt (a) ovan.
Styrelsen anser att ett lägre kvotvärde är mer ändamålsenligt för Bolagets aktiekapitalstruktur. Efter minskningen av aktiekapitalet kommer Bolagets aktiekapital att uppgå till 15 509 308,55 kronor, fördelat på sammanlagt 310 186 171 aktier, varav 600 000 A-aktier som ger rätt till tio (10) röster per aktie på bolagsstämma och 309 586 171 B-aktier som ger rätt till en (1) röst per aktie på bolagsstämma. Samtliga aktier kommer efter minskningen att ha ett kvotvärde om 0,05 kronor per aktie.
Beslutet om att minska Bolagets aktiekapital i enlighet med detta förslag kräver tillstånd från Bolagsverket eller allmän domstol.
Punkt 14 – Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Styrelsen föreslår att stämman bemyndigar styrelsen, den verkställande direktören eller den styrelsen i övrigt förordnar att vidta sådana smärre justeringar och förtydliganden av de på stämman fattade besluten i den utsträckning detta är erforderligt för registrering av besluten.
ÖVRIGT
Majoritetskrav
För giltigt beslut enligt förslag till beslut enligt punkterna 12 och 13 krävs att det biträds av aktieägare med minst två tredjedelar (2/3) av såväl de avgivna rösterna som de aktier som är företrädda vid bolagsstämman.
Aktieägares rätt att begära upplysningar
Aktieägare har av styrelsen och den verkställande direktören rätt begära upplysningar enligt 7 kap. 32 § aktiebolagslagen avseende förhållanden som kan inverka på bedömningen av ett ärende på dagordningen eller som kan inverka på bedömningen av bolagets ekonomiska situation. Styrelsen och den verkställande direktören ska lämna ut sådana upplysningar om styrelsen anser att det kan ske utan väsentlig skada för Bolaget.
Handlingar
Kallelsen, styrelsens fullständiga förslag till beslut, fullmaktsformulär samt redovisningshandlingar och revisionsberättelse för år 2024 och övriga handlingar enligt aktiebolagslagen kommer hållas tillgängliga för aktieägare hos Bolaget tre veckor före stämman samt sändas kostnadsfritt till de aktieägare som begär det och uppger sin postadress. Handlingarna kommer också publiceras på Bolagets hemsida (www.izafegroup.com), senast samma dag.
Behandling av personuppgifter
För information om hur dina personuppgifter behandlas i samband med bolagsstämman, se integritetspolicyn på Euroclear AB:s webbplats,
Det totala antalet aktier i Bolaget uppgår per dagen för denna kallelse till 310 186 171, varav 600 000 A-aktier och 309 586 171 B-aktier. Det totala antalet röster i Bolaget uppgår till 315 586 171 röster där varje A-aktie berättigar till tio (10) röster och varje B-aktie berättigar till en (1) röst.
iZafe Group AB (publ.) presents today, April 25th, its report for the first quarter.
Financial Performance in Summary
Total net revenue for the quarter amounted to 1,318 TSEK (3,410), now primarily consisting of recurring license revenues. This contrasts with the same period last year, when revenue was mainly driven by hardware sales, which in turn enable the generation of these recurring license revenues.
Operating result (EBIT) for the quarter amounted to -3,519 TSEK (-5,569).
Operating result before depreciation and amortization (EBITDA) for the quarter amounted to -2,538 TSEK (-4,588), a clear improvement despite lower revenue compared to the same period last year. This reflects a more profitable revenue mix and increased operational efficiency.
Result after financial items for the quarter amounted to -3,779 TSEK (-5,609).
Cash flow from operating activities for the quarter amounted to -7,013 TSEK (-4,109).
Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
Equity per share at the end of the period amounted to 0.04 SEK (0.08).
The equity ratio at the end of the period was 53.2% (67.5%).
Significant events during the quarter
iZafe Group has completed a directed share issue of approximately SEK 9.2 million through the issuance of 46.15 million B-shares at a subscription price of SEK 0.20 per share. The capital will be used to strengthen working capital, accelerate growth, and support the expansion of Dosell and Pilloxa into new markets.
iZafe Group AB has initiated the sales of Dosell in Spain through its partnership with Ti-Medi. The product is launched under the Savioo Home brand and is now available through Ti-Medi’s network of over 1,500 pharmacies. Dosell enables automatic reminders and alerts in case of missed medication, improving adherence and safety for patients and their families. The launch marks an important milestone in iZafe Group’s international expansion.
iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB as its new Certified Adviser. Carnegie will assume the role on April 1, 2025, and until then, Mangold Fondkommission AB will continue to serve as the company’s Certified Adviser.
Significant events after the end of the quarter
iZafe Group AB has continued to grow during the quarter with an increase in billable Dosell units and strong demand in Sweden, the Netherlands, and Spain. Three new municipalities have initiated operations, the partner TCCN is launching Dosell TV in the Netherlands, and over 50 pharmacies in Spain have joined the Savioo Home concept. The company is experiencing growing commercial momentum and is engaged in discussions with new partners for continued expansion.
Forecast In this report, we present a forecast graph illustrating our expected growth in both ARR and active Dosell units over the coming years. The forecast is based on our current markets and key performance indicators, outlining a clear path toward an exponential increase in recurring revenue as more units become activated. By the end of 2024, our ARR reached approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year.
In 2025, this growth is expected to accelerate further, with ARR projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when we anticipate exceeding 85 MSEK. We will track this forecast on a quarterly basis to provide our shareholders with a clear view of our actual progress and how we are advancing toward our financial goals.
2023
2024
2025
2026
2027
2028
2029
ARR (MSEK)
0.3
1.7
10
22.5
42.3
63.9
85.5
Growth of Dosells
0%
467%
488%
125%
88%
51%
34%
Comments from the CEO 2025 has started strong for iZafe Group, and we are now entering the next phase of our growth journey. We can clearly see how previous deliveries of Dosell to our partners are now bearing fruit in the form of recurring license revenues – the most profitable part of our business model. Our focus on scalability, recurring revenues, and international expansion is beginning to show tangible financial results.
During the first quarter, the number of active Dosell units has continued to grow rapidly. It is now – as these units are activated and used daily – that we are realizing the value of the investments and deliveries made throughout 2024. Our ARR at the end of the quarter surpassed 3 MSEK, confirming that we are on track to meet our financial targets for the year. This development is fully in line with the growth forecast we presented in the previous quarterly report and clearly shows that our business model is scaling as expected.
The shift towards recurring revenues improves profitability
Even though net revenue in Q1 2025 (1.3 MSEK) is lower than the corresponding quarter last year, the result has improved significantly. This is thanks to a larger share of revenues now being license-based with high margins – a direct effect of the increased activation rate among our partners. Operating profit improved by more than 2 MSEK compared to Q1 2024, providing clear evidence that our strategy is working.
We have now established a recurring revenue model that is scalable, predictable, and profitable. As more Dosell units are activated, revenues grow without a corresponding increase in the cost base – a powerful shift that lays the foundation for cash flow positivity and long-term profitability.
Momentum across multiple markets
During Q1, we have continued to increase our presence and demand in our key markets:
– Sweden: We have now launched Dosell in 14 new municipalities so far this year, with several more in the pipeline. An increasing number of municipalities are moving from pilot projects to full implementation, demonstrating that we have found the right fit in both product and offering. Demand is driven by safety, simplicity, and increased efficiency in home care services.
– Netherlands: Our partner TCCN has reported continued strong activation rates, including 72 units delivered to their customer MobileCare during March. The launch of Dosell TV and exposure at trade fairs are creating additional momentum. The Netherlands is now a mature growth market for us.
– Spain: Our Spanish partner Ti-Medi has officially launched Dosell as part of its Savioo platform. Over 50 pharmacies have already joined the concept. This gives us access to a rapidly growing market with a high proportion of dose pouch users and strong demand for digital solutions.
Strengthened liquidity after the end of the quarter
At the end of the quarter, cash and cash equivalents amounted to approximately 0.7 MSEK, reflecting the investments we have made to accelerate our expansion. However, it is important to highlight that half of the previously communicated directed share issue of approximately 9.2 MSEK was received by the company in April. This means that our cash position has been significantly strengthened after the period, creating better conditions to continue executing our growth plan.
Focus on real impact – and what truly matters
We now have strong momentum in the business, with the number of Dosell units loaded with medication and dispensing daily increasing month by month. This development forms the foundation for both our long-term growth and the societal benefit we aim to deliver.
Our most important key metric is not simply how many units we have sold or are billing licenses for, but how many times we have ensured correct medication. So far, we have surpassed over 400,000 doses dispensed at the right time – each dose representing a moment of safety for the user, reduced strain on healthcare providers, and improved adherence.
A new phase – moving full speed ahead
In a short time, we have established a product that is in demand, a scalable business model, and a clear growth strategy. During the quarter, we have further improved the product with a new software version, maintained our cost focus, and strengthened our customer relationships. The momentum we now see – both in actual usage and business development – is clear evidence that something has shifted.
In parallel, we continue to engage in discussions with new potential partners, both in existing and new markets, with the aim of expanding our presence and reaching more patients through the right local collaborations.
We are entering a breakthrough year where the focus is on continuing to scale, streamline operations, and create value – for our users, partners, society, and our shareholders.
Thank you to all employees, partners, and shareholders who make this journey possible.
Anders Segerström Chief Executive Officer, iZafe Group
After an increase of billable Dosell units by 25% in January and an additional 9% in February, the number rose by another 12% in March. This is a clear indication that our strategy is working and that demand for our solution continues to grow.
At the same time, it’s important to emphasize that we are still in an early stage. Growth is occurring from relatively low levels, but the pace is exceptional. During the first quarter of 2025, we activated as many units delivering medication daily as we had over the entire first five years since the original version of Dosell was developed – a significant milestone.
Our business model now shows clear scalability, with more active Dosell units generating a growing stream of recurring revenue. We are entering a commercial breakthrough phase with record-high momentum, fueled by demand from both municipalities and international partners.
Sweden: More municipalities onboard – focus on long-term expansion In March, three new municipalities began using Dosell. We also signed a direct procurement agreement with a municipality that, after completing a pilot, decided to fully transition to Dosell from a previously used solution. They highlight its simplicity, reliability, and the fact that doses are not locked if missed – giving both users greater independence and care services increased flexibility in scheduling.
Another municipality has launched a pilot under our structured “municipal package,” and we have several ongoing tenders within home care and LSS (disability services). Every week, we receive new inquiries – a clear signal of a shifting market where scalable, modern solutions are increasingly in demand.
At the same time, it is important to point out that volumes per municipality are still relatively low. Our focus moving forward is to support each municipality in identifying more users, increasing usage, and maximizing societal benefit. As the population ages, care must scale – and with digital tools like Dosell, we can ensure safe and high-quality care for more people without overburdening resources.
The Netherlands: Strong customer onboarding and launch of Dosell TV In the Netherlands, we continue to meet our growth forecast. Our partner TCCN reports that their largest customer, MobileCare, delivered an additional 72 units in March. Interest is growing steadily, with more organizations joining the system each week.
In April, TCCN is launching the first broadcast of Dosell TV – a new platform to share knowledge, inspire, and support new organizations in getting started. It is a concrete step towards scaling implementation and building a vibrant user and partner community. In parallel, TCCN is also exhibiting Dosell at a major trade fair in the Netherlands in April – a key opportunity to reach new customers and further strengthen our market position.
Spain: Pharmacy network and strong role in Savioo Home The launch of Dosell in Spain through the Savioo Home concept is now underway. Our partner has attended several trade fairs in Barcelona and France, where Dosell was presented as a central component for ensuring proper medication adherence at home.
Over 50 pharmacies have already expressed interest in adopting the concept and will soon receive promotional materials for in-store and window displays. This is only the beginning – these 50 pharmacies are the first wave in a network of 1,500 that our partner is actively working with. The ambition is high, and we see a serious, long-term effort that lays the foundation for success.
Expansion: Engaging new markets and new partners We are currently in active discussions with new potential partners, both in existing and new geographies. Interest is coming from both public and private sectors, all recognizing the need for digital medication management. Our strategy remains clear: grow with the right partners – those with the drive and ability to scale.
To Our Shareholders – Why We Believe in Our Direction iZafe Group is stronger than ever. We have a highly demanded solution, a growing customer network, and a proven business model. At the same time, we remain humble about the fact that we are still in a building phase – but something has clearly shifted.
We’ve set a new pace in the market, delivering more active units in one quarter than in our first five years combined – and this is just the beginning. With the momentum we’re experiencing, combined with our long-term strategy, our belief is stronger than ever: Dosell has the potential to become a cornerstone in the future of medication management.
Thank you for following our journey – and for your continued trust.
iZafe Group AB (publ) announces today that the company is changing its Certified Adviser from Mangold Fondkommission AB to Carnegie Investment Bank AB (publ).
iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB regarding the role as Certified Adviser. Carnegie Investment Bank AB will assume the role of Certified Adviser on April 1, 2025. Until then, Mangold Fondkommission AB will continue to act as the company's Certified Adviser.
